Business Wire

ORAL-B

16.5.2024 01:02:35 CEST | Business Wire | Press release

Share
New Award Programme From Oral-B and the International Association for Disability and Oral Health (iADH) Champions Disability Positive Dental Practices Across Europe

Today, on Global Accessibility Awareness Day (GAAD), Oral-B proudly launches the Disability Champions Award Programme as part of its ongoing mission to make oral care more accessible to everybody. In partnership with the iADH, the programme aims to make the dentist office experience across Europe more inclusive and positive for those with disabilities and their caregivers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515281762/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Benjamin Binot, P&G Europe Oral Care Senior Vice President, announcing the launch of the Disability Champions Awards Programme and previewing the new iO2 toothbrush at Oral-B’s ‘Championing the Perfect Clean for All’ event in Amsterdam. (Photo: Business Wire)

Over a third (36%) of people with visible and non-visible disabilities feel anxious or frustrated when it comes to visiting the dentist. For instance, individuals with Autism Spectrum Disorder may experience heightened anxiety in unfamiliar environments such as a dental practice, as it disrupts their normal routine. Similarly, a patient with Cerebral Palsy, who may face motor challenges without intellectual disability, might find it difficult to brush their teeth effectively due to limitations in fine motor coordination.

To help overcome this, the Disability Champions Award Programme encourages one member of each dental practice across Europe to become the personal lead to ensure their practice is committed to be more disability positive – because sometimes all it takes is one person to truly make a difference.

By completing the necessary online training and accessibility suggestions devised by iADH and Oral-B (available at https://www.iadh.org/oral-b-iadh-disability-champions/) dental staff who meet the requirements will earn their Disability Champions award. They receive a badge that can be used within their office or on social media to encourage others to become Disability Champions. Their practice will also be visible on Oral-B’s website to make it easier for people with disabilities and their caregivers to find disability positive dental practices near them, and to feel more confident and encouraged about visiting the dentist.

Benjamin Binot, P&G Europe Oral Care Senior Vice President, said: “Last year, we launched The Big Rethink initiative in partnership with iADH to rethink how Oral-B can make oral care more inclusive, accessible, and positive for people with disabilities, their caregivers, and everyone in between. This year, we are making our intention good by driving action amongst dental practitioners with the Disability Champions Awards Programme. With our long-term partners, the iADH, we have devised a programme that is straightforward for dental staff to undertake and promote, and that demonstrates their commitment to raising the standard of oral care for people with disabilities.”

Professor. Pedro Diz Dios, President Elect of iADH, said: “At the iADH, we are about promoting equitable oral care. However, we often find that dental practitioners have pre-conceived notions of what makes their practice inclusive, accessible, and positive for people with disabilities and their caregivers. We want to help dentists rethink how to provide a better service for all and believe that appointing one person in the organization to become a Disability Champion will help drive the right change forward. The hope is that as many dental practices as possible across Europe take part in the Disability Champions Award Programme and make better oral care for all a reality.”

The Disability Champions Awards Programme is being launched at Oral-B’s ‘Championing the Perfect Clean for All’ global event being held in Amsterdam between 15-16th May. Over 100+ media, dental professionals and people with disabilities will learn more about the programme, hear inspiring stories from the latest Disability Champions, and experience first-hand how Oral-B plans to bring a better oral care experience to people with disabilities - at the dentist practice and at home. Indeed, Oral-B is previewing its new Oral-B iO2 toothbrush that will bring its revolutionary iO technology to a wider audience, including people with disabilities.

The iO2 is crafted to effortlessly transition manual toothbrush users to electric toothbrushes by bringing Oral-B’s iO technology to life with one simple touch for a simpler, more intuitive cleaning experience that’s tough on plaque and gentle on gums! The dentist-inspired round brush head surrounds teeth, perfectly adapting to their unique shape, removing 100% more bacterial plaque than regular manual brushes even in hard-to-reach areas of the mouth. The iO2 will also come with a new brush head with Smart Bristles that now fully fade their colour to white, making it easy to know when it's time to change your brush head.

1 The Oral Health & Disability European Study (2022) surveyed 5,000 respondents across UK, France, Germany and Italy

Notes to editor:

  • About the research: The Oral Health & Disability European Study (2022) surveyed 5,000 respondents across UK, France, Germany and Italy, and was conducted by Reputation Leaders on behalf of Oral-B
  • For more information on The Disability Champions Awards Programme, please visit here. The website offers relevant and helpful content for people with disabilities, their caregivers, and families, as well as the professional community.
  • Please contact your local Oral-B press office for more information and on local availability of iO2

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bold®, Braun®, Daz®, Fairy®, Febreze®, Gillette®, Head & Shoulders®, Herbal Essences®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, Tampax®, Venus® and Vicks®.

Although headquartered in the US, P&G was founded by an Englishman and an Irishman in 1837, our heritage lives on through the work of Research & Development Centres, Manufacturing Plants and Business sites, across the UK & Ireland.

Beyond our Purpose, Values & Principles, the foundation on which P&G was built and our guiding force for over 180 years, we aspire to be a force for growth so that we can be a force for growth in the communities in which we live and work. Through our citizenship priorities, we want to build a better world for all of us - inside and outside of P&G - free from gender bias, with equal voice and equal representation. Environmental sustainability is embedded into our business, and has been for decades, and we have a strong track record of delivering on our goals in this area. We support communities around the world through our people, our brands and our partners by delivering the comforts of home, health and hygiene.

About Oral-B

Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.

About the International Association for Disability and Oral Health (iADH)

The iADH is a global organization with over 8000 members from all sectors of health and social care interested in disability and oral health who work to share their scientific knowledge, research, clinical skills and collective experience to reduce barriers to care and improve oral health outcomes for people with disability.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515281762/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye